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Abstract
Introduction  BRCA1  and  BRCA2  mutation carriers are at
increased risk for developing both breast and ovarian cancer. It
has been suggested that carriers of BRCA1/2 mutations may
also be at increased risk of having recurrent (three or more)
miscarriages. Several reproductive factors have been shown to
influence the risk of breast cancer in mutation carriers, but the
effects of spontaneous and therapeutic abortions on the risk of
hereditary breast cancer risk have not been well studied to date.
Methods In a matched case-control study, the frequencies of
spontaneous abortions were compared among 1,878 BRCA1
mutation carriers, 950 BRCA2  mutation carriers and 657
related non-carrier controls. The rates of spontaneous and
therapeutic abortions were compared for carriers with and
without breast cancer.
Results There was no difference in the rate of spontaneous
abortions between carriers of BRCA1 or BRCA2 mutations and
non-carriers. The number of spontaneous abortions was not
associated with breast cancer risk among BRCA1 or BRCA2
mutation carriers. However, BRCA2 carriers who had two or
more therapeutic abortions faced a 64% decrease in the risk of
breast cancer (odds ratio = 0.36; 95% confidence interval
0.16–0.83; p = 0.02).
Conclusion Carrying a BRCA1 or BRCA2 mutation is not a risk
factor for spontaneous abortions and spontaneous abortions do
not appear to influence the risk of breast cancer in carriers of
BRCA1 or BRCA2 mutations. However, having two or more
therapeutic abortions may be associated with a lowered risk of
breast cancer among BRCA2 carriers.
Introduction
Germline mutations in BRCA1 (MIM # 113705) and BRCA2
(MIM # 600185) are estimated to account for about 80% of
breast/ovarian cancer families and 20% to 50% of site-spe-
cific breast cancer families [1-3]. Mutation carriers face sub-
stantially increased risks of developing both breast and ovarian
cancer; the lifetime risk for developing breast cancer in
BRCA1/2 mutation carriers is estimated to be 40% to 85% (4
to 7-fold greater risk than the general population) and for ovar-
ian cancer to be 16% to 64% (a 30-fold increase) [3-5].
Reproductive factors have been shown to modify the risk of
breast cancer risk in both mutation carriers [6] and the general
population [7,8]. However, the relationships between induced
or spontaneous abortions and breast cancer risk in BRCA1 or
BRCA2 carriers have not been well studied. A recent study
from Israel suggested that BRCA1/2 mutation carriers might
be at increased risk for recurrent spontaneous abortions, com-
pared to non-carrier controls [9]; however, this study was rel-
atively small. To date, there has been no published large-scale
analysis of the possible effect of being a BRCA1 or BRCA2
mutation carrier on the rate of spontaneous abortions. The
dual aims of this study were: to assess the effect of being a
carrier of a germ-line BRCA1 or BRCA2 mutation on the risk
of spontaneous abortion; and to investigate whether or not
there is an association between spontaneous or therapeutic
abortions and the risk of breast cancer in women with a
BRCA1 or BRCA2 mutation.
Materials and methods
Study population
Eligible study subjects included living women who were iden-
tified at one of 55 participating centers in 8 countries. These
women were participants in ongoing clinical research proto-
cols at the host institutions. All study subjects (with the excep-
tion of those from the University of Utah) received counseling,
provided written informed consent for genetic testing and
completed a questionnaire that asked for all relevant informa-
tion regarding family history, reproductive and medical histo-
ries, and selected lifestyle factors, including smoking and the
use of oral contraceptives. Questionnaires were administered
at the individual centers at the time of a clinic appointment or
at their home at a later date. Questions addressing fertility his-
tory included 'have you ever been pregnant' (yes/no); and the
outcome of each pregnancy (for instance, spontaneous abor-
tion, therapeutic abortion, still born, or live born).
The institutional review boards of the host institutions
approved the study. In most cases, testing was initially offered
to women who had been affected with breast or ovarian can-
cer. When a BRCA1 or BRCA2 mutation was identified in a
proband or relative, genetic testing was offered to other at-risk
women in the family. Mutation detection was performed using
a range of techniques, but all nucleotide sequences were con-
firmed by direct sequencing of DNA. A woman was eligible for
the current study when the molecular analysis established that
she was a carrier of a deleterious mutation in the BRCA1 or
BRCA2 gene. Most (>95%) of the mutations identified in the
study subjects were nonsense mutations, deletions, inser-
tions, or small frameshifts, and clearly considered deleterious
and pathogenic.
Part 1
The aim of the first part of the study was to examine whether
the presence of a BRCA mutation influences the rate of spon-
taneous abortions. Non-carrier controls were women who
underwent genetic testing and were found not to be carriers
of a deleterious BRCA1 or BRCA2 mutation. These women
were from families where a mutation had previously been iden-
tified, who underwent genetic testing at the Centre for
Research in Women's Health in Toronto and were found not
to carry the family mutation. Since information was not availa-
ble for European or Israeli controls, we limited this analysis to
Canadian and American women (carriers and non-carriers)
who had at least one pregnancy and from centers that pro-
vided information on all pregnancies, including therapeutic
and spontaneous abortions. Potential subjects were excludedAvailable online http://breast-cancer-research.com/content/8/2/R15
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if information regarding pregnancy or the number of spontane-
ous abortions was missing. Women who had experienced
ovarian cancer prior to breast cancer were also excluded. After
exclusion, a total of 3,503 women were available for this part
of the study, including 1,878 BRCA1 mutation carriers, 950
BRCA2 mutation carriers, 18 women with mutations in both
genes, and 657 non-carrier controls.
Part 2
Second, we examined whether there is an association
between spontaneous or therapeutic abortions and the risk of
breast cancer in BRCA1 and BRCA2 mutation carriers. There
was information on cancer history and mutation carrier status
for a total of 6,993 women from 55 participating centers who
carried a BRCA1 or BRCA2 mutation. Potential case subjects
were selected from among the study subjects with a diagnosis
of invasive breast cancer. Control subjects were women who
never had breast cancer and who were carriers of a mutation
in the BRCA1  or BRCA2 gene. This study was limited to
parous women; therefore, potential subjects were excluded if
the women were nulliparous or information on pregnancy was
missing (923 women). Not all centers provided data on spon-
taneous abortions, and data regarding spontaneous abortions
was missing for 1,230 women. Potential subjects were
excluded if they had been diagnosed with ovarian cancer prior
to breast cancer (57 women), if information about ovarian can-
cer was missing (2 women), if information regarding preventive
surgery (bilateral mastectomy or oophorectomy) was missing
(109 women), or if information regarding the date of interview
was missing (5 women). After exclusions, a total of 4,669
women were eligible, including 2,281 women with breast can-
cer (potential cases) and 2,388 women without breast cancer
(potential controls).
Statistical analyses
Part 1
The Student's t test was used to compare the number of spon-
taneous abortions between carriers and non-carriers. The car-
rier group was divided into BRCA1 and BRCA2 carriers. This
analysis was restricted to carriers and non-carriers from North
America.
Part 2
A matched case-control analysis was carried out to test for a
possible association between a spontaneous or therapeutic
abortion and the risk of breast cancer in BRCA mutation car-
riers. A single BRCA mutation carrier (case) was selected for
each unaffected subject (control), matched according to
mutation in the same gene (BRCA1 or BRCA2), year of birth
(within one year), and country of residence. A diagnosis of
ovarian or other form of cancer in the control had to be after
the year of diagnosis of the matched case subject. In addition,
the date of interview of the controls, age of protective bilateral
oophorectomy or age of bilateral mastectomy of the control
subject was required to be after the date of breast cancer
diagnosis of the matched case subject. A total of 1,694
matched case-control pairs were generated for the analysis,
including 1,313 pairs with BRCA1 mutations, 380 pairs with
BRCA2 mutations, and one pair with both mutations. The mul-
tivariate odds ratios (ORs), 95% confidence intervals (CIs)
and tests for linear trend were estimated by use of conditional
logistic regression. A multivariate analysis was carried out to
control for the potential confounding effects of age at
menarche (years), parity (0, 1, 2, 3, 4+), age of first birth
(years), oophorectomy (yes/no), and oral contraceptive use
(ever/never). The chi square test was used to test for differ-
ences in categorical variables. All statistical tests were two-
Table 1
Comparison of spontaneous abortions among BRCA mutation carriers and non-carriers
All carriers BRCA1 BRCA2 Non-carriers
Age (mean) 49.7 48.8 51.3 46.7
Year of birth (mean) 1950 1951 1948 1951
Number of full-term pregnancies 2.38 2.36 2.42 2.43
Number of spontaneous abortions
Never 2,103 (73.9%) 1,404 (74.8%) 688 (72.4%) 478 (72.8%)
Ever 743 (26.1%) 474 (25.2%) 262 (27.6%) 179 (27.2%)
1 527 (18.5%) 332 (17.7%) 189 (19.9%) 134 (20.4%)
2 145 (5.1%) 95 (5.0%) 49 (5.2%) 30 (5.0%)
3+ 71 (2.5%) 47 (2.5%) 24 (2.5%) 15 (2.3%)
Mean 0.38 0.37 0.40 0.38
Eighteen subjects had a mutation in both BRCA1 and BRCA2.Breast Cancer Research    Vol 8 No 2    Friedman et al.
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sided. All analyses were performed using the SAS statistical
package, version 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Part 1: BRCA mutations, parity and spontaneous 
abortions
There was no significant difference in the number of women
who had a spontaneous abortion, or in the mean number of
spontaneous abortions, between carriers and non-carriers
(Table 1). On average, the non-carriers were born six months
after the carriers, so the two groups were similar with respect
to age and birth cohort. Because BRCA1 and BRCA2 muta-
tions are several times more common in the Jewish than non-
Jewish population, the analysis was repeated, but restricted to
Jewish subjects (Table 2). Three or more spontaneous abor-
tions were experienced by 2.9% of Jewish carriers, 2.3% of
non-Jewish carriers and 2.3% of all controls. Among Jewish
women, 2.4% of BRCA1 carriers, 4.3% of BRCA2 carriers
and 0% of non-carrier controls experienced three or more
abortions. There were significantly more women with three or
more miscarriages among the Jewish BRCA2 carriers than
among the Jewish non-carrier controls (4.3% versus 0%; p =
0.03), but these subgroups were small and no Jewish control
had 3 or more miscarriages.
Part 2: Spontaneous and therapeutic abortions and the 
risk of breast cancer in BRCA mutation carriers
The aim of the second part of this study was to examine
whether there was an association between the number of
abortions (both spontaneous and therapeutic), and the risk of
breast cancer among BRCA mutation carriers. This analysis
was limited to parous women. We compared BRCA mutation
carriers with and without breast cancer. Case and control sub-
jects were matched for year of birth, mutation status and coun-
try of residence (Table 3). They had similar histories of oral
contraceptive use, but case subjects had, on average, a signif-
icantly earlier age at menarche than the control subjects (12.9
versus 13.0 years; p = 0.001) and were less likely to have had
Table 3
Comparison of case and control subjects with BRCA1 and 
BRCA2 mutationsa
Variable Case subjects 
(N = 1,694)
Control subjects 
(N = 1,694)
P value
Current age 
(mean)
49.3 48.6 0.22
Year of birth 
(mean year)
1951.2 1951.8 0.10
Mutation, N (%)
BRCA1 1,313 (77.5%) 1,313 (77.5%)
BRCA2 380 (22.4%) 380 (22.4%)
Country of residence, N (%)
United States 591 (34.9%) 591 (34.9%)
Canada 
(excluding 
Quebec)
491 (29.0%) 491 (29.1%)
Poland 439 (25.9%) 439 (25.9%)
Israel 102 (6.0%) 102 (6.0%)
Norway 55 (3.2%) 55 (3.2%)
Sweden 7 (0.4%) 7 (0.4%)
United 
Kingdom
6 (0.4%) 6 (0.4%)
Austria 1 (0.1%) 1 (0.1%)
Italy 2 (0.1%) 2 (0.1%)
Parityb, mean 2.2 2.2
Oophorectomy 61 (3.6%) 109 (6.4%) 0.0002
Oral contraceptive use, N (%)
Ever 1,002 (59.8%) 1,009 (60.1%) 0.89
Age at menarche, 
mean
12.9 13.0 0.001
aParity, miscarriages, and therapeutic abortions were censored one 
year prior to the breast cancer diagnosis of the case. Data for age at 
menarche, parity and therapeutic abortions are missing for a few 
study subjects. bParity includes live born and still born only, and was 
included in analysis only if birth was one calendar year before the age 
of diagnosis of the matched case.
Table 2
Comparison of spontaneous abortions among Jewish BRCA 
mutation carriers (n = 795) and non-carriers (n = 110)
All carriers BRCA1 BRCA2 Non-
carriers
Age (mean) 51.5 51.1 52.8 47.6
Year of birth 
(mean)
1947.8 1948.1 1946.8 1950.5
Number of full-
term 
pregnancies
2.15 2.11 2.24 1.94
Number of 
spontaneous 
abortions
Never 595 
(74.8%)
436 
(75.7%)
154 
(73.3%)
78 
(70.9%)
Ever 200 
(25.2%)
140 
(24.3%)
56 
(26.7%)
32 
(29.1%)
11 4 0  
(17.6%)
100 
(17.4%)
36 
(17.2%)
27 
(24.5%)
2 37 (4.7%) 26 (4.5%) 11 (5.2%) 5 (4.6%)
3+ 23 (2.9%) 14 (2.4%) 9 (4.3%) 0 (0.0%)
Mean 0.37 0.34 0.44 0.34
The decimal place (0.0–0.999) following the Year of Birth refers to 
percentage of 365 days. For example, if a mutation carrier was born 
on June 30, 1996, this would translate to 1996.5.Available online http://breast-cancer-research.com/content/8/2/R15
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an oophorectomy than controls (3.6% versus 6.4%; p =
0.0002).
There was no association between the mean number of spon-
taneous abortions and breast cancer risk in either BRCA1 car-
riers or BRCA2 carriers (Table 4). Furthermore, there were no
differences in the rate of recurrent (three or more) abortions
between cases and controls for either BRCA1  carriers or
BRCA2 carriers (Table 4).
The number of therapeutic abortions was not associated with
the risk of breast cancer in BRCA1 carriers; however, among
women who carried a deleterious BRCA2 mutation, ever hav-
ing had a therapeutic abortion was inversely associated with
the risk of breast cancer (Table 5). On average, affected
BRCA2 carriers had 0.17 therapeutic abortions, versus 0.29
for unaffected BRCA2  carriers (p = 0.005). Compared to
women who never had an abortion, BRCA2 mutation carriers
who had two or more abortions had a 64% decrease in the risk
of breast cancer (OR = 0.36; 95% CI 0.16–0.83; p = 0.02).
A protective effect of incomplete pregnancies among BRCA2
mutation carriers remained when we assessed the relationship
between the total number of spontaneous and therapeutic
abortions and breast cancer risk. Among BRCA2 mutation
carriers, the mean number of spontaneous and therapeutic
abortions in total was significantly lower in the cases versus
the control subjects (0.69 versus 0.52, p = 0.009). Having had
two or more spontaneous or therapeutic abortions resulted in
a significant reduction in risk (OR = 0.56; 95% CI 0.36–0.89;
p-trend = 0.009) among women with a BRCA2 mutation. The
effects of spontaneous and therapeutic abortions, alone and in
combination, are presented in Table 6.
Discussion
Several epidemiological studies have reported that induced or
spontaneous abortions are risk factors for breast cancer in the
general population [10,11]. However, a collaborative analysis
of data from 53 studies, encompassing 83,000 women from
16 countries, concluded that pregnancies that ended in spon-
taneous or induced abortion did not increase a woman's risk
of developing breast cancer [12]. Similar results were
obtained subsequently from a study of African-American
women [13] and from a prospective study of young women
[14]. However, these studies focused on women from the gen-
eral population, and did not specifically address subgroups of
high-risk women. Thus, the results cannot be directly extrapo-
lated to women with a genetic predisposition.
In a previous study of miscarriages among Israeli Jewish
women, 4.4% of 343 BRCA mutation carriers and 3% of 400
non-carriers reported 3 or more spontaneous abortions [9].
These rates of recurrent abortions are similar to those found in
Table 5
Therapeutic abortions among affected and unaffected BRCA 
mutation carriers
Number of 
therapeutic 
abortions
Cases Controls OR(95% CI) P value
BRCA1 carriers
Never 1,120 1,109 1
Ever 192 202 0.98 (0.78–1.22) 0.84
1 137 144 0.97 (0.75–1.26) 0.82
2+ 55 58 1.00 (0.68–1.47) 0.99
Mean 0.21 0.22 0.68
BRCA2 carriers
Never 329 308 1
Ever 51 72 0.64 (0.41–1.00) 0.05
1 39 44 0.77 (0.47–1.25) 0.29
2+ 12 28 0.36 (0.16–0.83) 0.02
Mean 0.17 0.29 0.005
Odds ratios adjusted for age at menarche (years), parity (0, 1, 2, 3, 
4+), age of first birth (years), oral contraceptive use (ever/never) and 
oophorectomy (ever/never).
Table 4
Spontaneous abortions among affected and unaffected BRCA 
mutation carriers
Number of 
spontaneous 
abortions
Cases Controls OR (95% CI) P value
BRCA1 carriers
Never 1,022 1,032 1
Ever 291 281 1.09 (0.89–1.32) 0.42
1 210 195 1.14 (0.90–1.43) 0.28
2 53 59 0.94 (0.63–1.42) 0.77
3+ 28 27 1.05 (0.61–1.81) 0.86
Mean 0.32 0.31 0.70
BRCA2 carriers
Never 295 266 1
Ever 85 114 0.75 (0.55–1.04) 0.09
1 58 83 0.71 (0.48–1.04) 0.08
2 16 23 0.65 (0.33–1.26) 0.20
3+ 11 8 1.54 (0.59–4.01) 0.38
Mean 0.35 0.41 0.30
Odds ratios adjusted for age at menarche (years), parity (0, 1, 2, 3, 
4+), age of first birth (years), oral contraceptive use (ever/never) and 
oophorectomy (ever/never).Breast Cancer Research    Vol 8 No 2    Friedman et al.
Page 6 of 7
(page number not for citation purposes)
the present study. We also found a higher frequency of recur-
rent abortions among Jewish BRCA2 carriers compared to
Jewish non-carrier controls (4.3% versus 0%; p = 0.03), but
the sample of Jewish controls was small. It is widely held that
homozygous carriers of BRCA1 or BRCA2 germline muta-
tions are non-viable, and it might, therefore, be expected that
25% of conceptions arising from marriages between carriers
of mutations in the same gene would end in miscarriage. How-
ever, the frequency of marriages between carriers is expected
to be low and this phenomenon is unlikely to contribute signif-
icantly to the overall miscarriage rate. Furthermore, it is not
known at what gestational age the homozygous fetus is likely
to miscarry, and if this is an early phenomenon it may be unno-
ticed. Assuming that 1% of Ashkenazi individuals carry a
BRCA1 mutation, and if they marry among Ashkenazis at ran-
dom, then 2.5 per 1,000 of the offspring of carrier women
should be homozygous. Given that the proportion of pregnan-
cies that ended in miscarriages among the Jewish women in
our study was 15%, or 150 per 1,000, we would expect only
2% of miscarriages among the offspring of carrier women to
be due to the excess of homozygote conceptions. The propor-
tion in non-Ashkenazi carriers would be much less.
The results of the second part of the study demonstrate that
spontaneous abortions do not influence the risk of breast can-
cer among women with either a BRCA1 or BRCA2 mutation.
However, ever having had a therapeutic abortion was associ-
ated with a 26% reduction in risk among BRCA2 mutation car-
riers. Two or more therapeutic abortions resulted in a 64%
decrease in breast cancer risk (OR = 0.36; 95% CI 0.16–
0.83; p = 0.02). We observed no association between thera-
peutic abortions and risk among women with a BRCA1 muta-
tion (OR for 2 or more therapeutic abortions = 1.00; 95% CI
0.68–1.47). Furthermore, we also found that combined spon-
taneous and therapeutic abortions conferred protection
against BRCA2 breast cancers. The results from this study
suggest a reduction in the risk of breast cancer in BRCA2
mutation carriers with a history of interrupted pregnancies.
However, the number of BRCA2 mutation carriers was rela-
tively small.
Although ours is a large study, there are several potential limi-
tations that must be considered. Our carrier population is com-
posed of women who seek genetic testing and these women
may differ systematically from women in the general popula-
tion, in terms of demographic features and reproductive histo-
ries. For example, it has been shown that women with children
are more likely to seek testing than women without children
[6]. However, this is likely to be due to a woman's concern for
passing down the mutation to her children, and it is not clear
that this is also the case for spontaneous or induced abortions.
Secondly, this is a case-control study and women with and
without breast cancer were asked to report on their past his-
tories of spontaneous and induced abortions. Women without
breast cancer may be more reluctant to disclose a previous
induced abortion than women with breast cancer. For this rea-
son, prospective studies are believed to be more reliable than
case-control studies for studying the effect of induced abor-
tions. Recently, the Collaborative Group on Hormonal Factors
in Breast Cancer [12] published breast cancer relative risk
estimates for both spontaneous and induced abortions,
derived from multiple studies. The estimates for spontaneous
abortion on breast cancer relative risk were 0.98 from both ret-
rospective and prospective studies. However, the estimate of
the effect of an induced abortion on breast cancer relative risk
was greater for case-control studies (OR = 1.11) than for ret-
rospective studies (OR = 0.93) attesting to the likelihood of
recall bias. Both estimates, however, were very close to unity.
Furthermore, in our study we observed a protective effect of
induced abortions on breast cancer risk in BRCA2 (but not in
BRCA1 carriers) and the direction of the observed effect is
opposite to that which we would expect from recall bias.
Various reproductive factors have been shown to exert differ-
ent effects on the risk of breast cancer among BRCA1 and
BRCA2  mutation carriers [15,16]. Recently, Cullinane and
colleagues [16] reported that increasing parity was a signifi-
cant risk factor among BRCA2 mutation carriers but was pro-
tective among BRCA1 mutation carriers. The authors found a
50% increased risk of breast cancer among women with a
BRCA2 mutation who had 2 or more children (OR 1.53; 95%
Table 6
Therapeutic and spontaneous abortions among BRCA1 and 
BRCA2 mutations carriers
Cases Controls OR (95% CI) P value
BRCA1 carriers
Neither 887 888 1
Therapeutic 
only
135 144 0.98 (0.74–1.26) 0.82
Spontaneous 
only
233 221 1.09 (0.87–1.35) 0.46
Either 368 365 1.04 (0.87–1.59) 0.69
Both 57 58 1.06 (0.71–1.59) 0.78
BRCA2 carriers
Neither 253 216 1
Therapeutic 
only
42 50 0.68 (0.42–1.11) 0.12
Spontaneous 
only
76 92 0.78 (0.55–1.11) 0.16
Either 118 142 0.75 (0.55–1.02) 0.06
Both 9 22 0.36 (0.14–0.88) 0.02
Odds ratios adjusted for age at menarche, parity, age of first birth, 
oral contraceptive use (ever/never) and oophorectomy (ever/never).Available online http://breast-cancer-research.com/content/8/2/R15
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CI = 1.01 to 2.32; p = 0.05). These results and those of the
present study suggest that the hormonal and/or developmen-
tal changes of a short-term pregnancy confer protection
against breast cancer in BRCA2 mutation carriers, whereas
those of a full-term pregnancy will increase the risk of breast
cancer. Jernstrom and colleagues [15] reported that breast-
feeding was protective among BRCA1 mutation carriers but
not among BRCA2  mutation carriers. The risk factors for
BRCA1  and  BRCA2  cancers appear to be different. It is
important, therefore, that specific risk profiles be developed for
carriers of BRCA1 and BRCA2 that can be used by genetic
counselors when discussing preventive strategies.
Conclusion
We found that miscarriages and therapeutic abortions do not
influence the risk of breast cancer in BRCA1 carriers. The
possibility of a protective effect of a therapeutic (and possibly
spontaneous) abortion among women with a BRCA2 mutation
requires further investigation.
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